📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
Waaree Renewable Bags 300MW/450MWp Solar EPC Order from Subsidiary
Waaree Renewable Technologies Limited (WAAREERTL) has secured a Letter of Award (LOA) for a 300MW/450MWp ground-mount solar project. The contract encompasses Engineering, Procurement, and Construction (EPC) services along with two years of Operation and Maintenance (O&M). The project is awarded by its subsidiary, Sunsational Power Private Limited, and is scheduled for completion within the financial year 2026-27. While it is a related party transaction, the company states it is conducted at arm's length.
Key Highlights
Secured EPC contract for a 300MW/450MWp ground-mount solar project.
Includes two years of Operation & Maintenance (O&M) services post-commissioning.
Project execution is scheduled for completion during the financial year 2026-27.
The order is from Sunsational Power Private Limited, a wholly-owned subsidiary of the company.
👀 What to Watch
Investors should view this as a boost to the company's order book and revenue visibility for FY27, though they should monitor the consolidated margin impact given it is an intra-group contract.
Hindware Home Innovation Increases Stake in Hintastica to 96.6% via 1.5 Cr Share Allotment
Hindware Home Innovation Limited has successfully increased its ownership in its subsidiary, Hintastica Private Limited (HPL), to 96.6%. This follows the allotment of 1,50,00,000 equity shares to the company under HPL's Rights Issue on June 4, 2026. The move represents a significant consolidation of control and capital infusion into the subsidiary. This update follows the initial disclosure regarding the investment made on June 3, 2026.
Key Highlights
Allotment of 1,50,00,000 equity shares in Hintastica Private Limited (HPL) to Hindware Home Innovation.
Hindware's total shareholding in HPL has increased to 96.6% of the paid-up share capital.
The allotment was finalized during HPL's board meeting held on June 4, 2026, at 4:30 P.M.
The transaction was conducted via a subscription to a Rights Issue.
👀 What to Watch
Investors should view this as a strategic consolidation of a subsidiary; monitor HPL's future performance to see how this capital infusion drives growth for the parent company.
Thyrocare to Hold 26th AGM on June 30; Sets June 23 as Record Date for Final Dividend
Thyrocare Technologies has scheduled its 26th Annual General Meeting (AGM) for June 30, 2026, to discuss the FY 2025-26 Annual Report. The company has fixed June 23, 2026, as the record date for determining shareholder eligibility for the final dividend. Shareholders can participate in remote e-voting between June 26 and June 29, 2026. Dividend payments are expected to be processed on or before July 29, 2026.
Key Highlights
26th Annual General Meeting scheduled for June 30, 2026, at 11:00 A.M. IST.
Record date for final dividend eligibility is Tuesday, June 23, 2026.
Dividend payment to be completed on or before Wednesday, July 29, 2026.
E-voting period starts June 26, 2026, and ends June 29, 2026.
Annual Report for FY 2025-26 and AGM Notice have been made available via digital links.
👀 What to Watch
Investors seeking the final dividend should ensure they hold shares by the June 23 record date. Shareholders are also encouraged to review the Annual Report to evaluate the company's financial health and strategic direction.
Thyrocare Sets June 23 as Record Date for ₹7.00 Final Dividend for FY26
Thyrocare Technologies has fixed June 23, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹7.00 per share for the financial year ended March 31, 2026. The dividend is subject to approval at the 26th Annual General Meeting (AGM) scheduled for June 30, 2026. If approved, the payout will be completed on or before July 29, 2026. This dividend represents a 70% payout on the face value of ₹10 per share.
Key Highlights
Final dividend of ₹7.00 per equity share recommended for FY 2025-26.
Record date for determining eligibility is Tuesday, June 23, 2026.
26th Annual General Meeting (AGM) scheduled for June 30, 2026.
Dividend payment to be completed on or before July 29, 2026.
👀 What to Watch
Investors interested in the dividend must ensure they hold the shares in their demat account before the ex-dividend date. Long-term investors should monitor the company's yield and payout consistency as part of their portfolio strategy.
Thyrocare FY26 Revenue Grows 21% to ₹829 Cr; PAT Surges 79% to ₹163 Cr; AGM on June 30
Thyrocare Technologies delivered a robust performance in FY 2025-26, with revenue from operations increasing 21% YoY to ₹829.04 crore. Profit After Tax (PAT) witnessed a massive 79% jump to ₹162.85 crore, driven by operational efficiencies and network expansion. The company expanded its lab footprint to 41 locations and its test menu to over 1,275 tests. Additionally, the company declared a dividend of ₹9.33 per share (restated for the 2:1 bonus issue) and successfully integrated Think Health for home ECG services.
Key Highlights
Revenue from operations grew 21% YoY to ₹829.04 crore in FY26 compared to ₹687.35 crore in FY25.
Profit After Tax (PAT) surged by 79% to ₹162.85 crore, up from ₹90.75 crore in the previous year.
Expanded laboratory network to 41 labs (including 7 new labs) and increased test menu to 1,275+ tests.
EBITDA increased by 34% YoY to ₹255.88 crore with a significant improvement in margins.
Proposed dividend of ₹9.33 per share, adjusted for the 2:1 bonus issue completed during the fiscal year.
👀 What to Watch
Investors should note the strong recovery in profitability and aggressive network expansion. The company's shift toward specialized diagnostics and home-based services like ECG makes it a competitive player in the diagnostic sector; hold for long-term growth.
Madras High Court Vacates Asset Alienation Injunction Against CARE Ratings
The Madras High Court has vacated an injunction order dated February 1, 2023, which had previously restrained CARE Ratings from alienating its assets. The vacation of this order on June 3, 2026, follows the company's compliance with court requirements to provide adequate security. This development restores the company's full control over its asset base, although the security was provided without prejudice to the company's ongoing legal appeals.
Key Highlights
Madras High Court vacated the injunction restraining asset alienation on June 3, 2026.
The original injunction had been in place since February 1, 2023, pending provision of security.
CARE Ratings complied with the security requirements to facilitate the lifting of the restriction.
The company received the formal court order on June 4, 2026.
Compliance was performed without prejudice to the company's rights in its ongoing appeals.
👀 What to Watch
Investors should view this as a positive development that removes a significant legal restriction on the company's balance sheet flexibility. Continue to monitor the final outcome of the underlying legal appeals.
Religare Allots 83.43 Lakh Equity Shares on Warrant Conversion; Raises Rs 147.05 Crore
Religare Enterprises Limited has allotted 83,43,263 equity shares following the conversion of warrants by five key investors, including Ashish Dhawan and JM Financial Credit Solutions. The company received the remaining 75% consideration amounting to Rs 147.05 crore, with the total issue price fixed at Rs 235 per share (including a premium of Rs 225). Consequently, the company's paid-up equity share capital has increased to Rs 341.23 crore, comprising 34,12,33,742 shares. These new shares will rank pari passu with existing shares but are subject to regulatory lock-in periods.
Key Highlights
Allotment of 83,43,263 equity shares of face value Rs 10 at a premium of Rs 225 per share.
Receipt of Rs 147.05 crore representing the final 75% payment for warrant conversion.
Key allottees include JM Financial Credit Solutions (25 lakh shares) and Ashish Dhawan (17 lakh shares).
Total paid-up equity capital increased from Rs 332.89 crore to Rs 341.23 crore.
The warrants were originally issued via preferential allotment following shareholder approval in August 2025.
👀 What to Watch
Investors should note the successful capital infusion and the participation of prominent investors, which signals confidence in the company's long-term prospects. While this leads to equity dilution, the strengthened balance sheet is a positive indicator for future growth.
Religare Enterprises Allots 83.43 Lakh Equity Shares on Warrant Conversion; Raises Rs 147 Cr
Religare Enterprises Limited has allotted 83,43,263 equity shares following the conversion of warrants by five key investors, including Ashish Dhawan and JM Financial Credit Solutions. The company received Rs 147.05 crore, representing the final 75% payment of the total consideration of Rs 235 per share. This conversion increases the company's paid-up equity capital from Rs 332.89 crore to Rs 341.23 crore. The move strengthens the balance sheet and reflects continued commitment from high-profile warrant holders.
Key Highlights
Allotment of 83,43,263 equity shares of face value Rs 10 at a premium of Rs 225 per share.
Receipt of Rs 147,05,00,104.25 representing the remaining 75% consideration for the warrants.
Key allottees include JM Financial Credit Solutions (25 lakh shares) and Ashish Dhawan (17 lakh shares).
Total paid-up equity share capital increased to Rs 341,23,37,420 comprising 34,12,33,742 shares.
The new shares will rank pari passu with existing equity shares, subject to SEBI lock-in regulations.
👀 What to Watch
Investors should note the capital infusion and the participation of marquee investors as a sign of long-term confidence. While there is a slight equity dilution, the strengthened capital base is beneficial for the company's growth prospects.
TTK Healthcare Sets July 17, 2026, as Record Date for Dividend and 68th AGM
TTK Healthcare Limited has announced July 17, 2026, as the record date for determining shareholder eligibility for its upcoming dividend and voting rights. The company's 68th Annual General Meeting (AGM) is scheduled to take place on July 24, 2026, at 12:00 PM via video conferencing. Shareholders must hold the stock by the record date to be eligible for the dividend payout and to participate in the voting process for corporate resolutions.
Key Highlights
Record date for dividend and voting rights fixed for July 17, 2026.
68th Annual General Meeting (AGM) scheduled for July 24, 2026, at 12:00 PM.
AGM to be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
Shareholders listed as of the cut-off date (July 17) will be eligible for the dividend distribution.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 17 record date. Existing shareholders should also prepare to participate in the virtual AGM to stay informed on company governance.
Hindware Home Innovation to Acquire 100% Stake in Hintastica JV for INR 2.79 Cr
Hindware Home Innovation Limited is set to acquire the remaining 50% stake in its joint venture, Hintastica Private Limited, from its French partner Atlantic for approximately INR 2.79 crore. Additionally, the company will invest up to INR 15 crore via a rights issue to provide working capital for Hintastica, which will become a wholly-owned subsidiary. This move follows Hintastica's transition to a distribution-led model after divesting its manufacturing facility in late 2025. The company has also extended a corporate guarantee of INR 25 crore to support the subsidiary's credit facilities.
Key Highlights
Acquisition of 5,48,787 equity shares from Atlantic for INR 2.79 crore to gain 100% ownership.
Board approved an additional investment of up to INR 15 crore through a rights issue for financial support.
Hintastica reported a turnover of INR 39.72 crore in FY26, down from INR 58.87 crore in FY25.
Extension of a corporate guarantee worth INR 25 crore to secure working capital for the new subsidiary.
Termination of the joint venture agreement with Atlantic Société Française de Développement Thermique.
👀 What to Watch
Investors should view this as a strategic consolidation that gives Hindware full control over its water heater business. Monitor the subsidiary's ability to scale its distribution-led model and improve profitability without the overhead of manufacturing.
Hindware to Acquire 100% Stake in Hintastica JV for ₹2.79 Cr; to Invest ₹15 Cr via Rights Issue
Hindware Home Innovation Limited is set to convert its joint venture, Hintastica Private Limited, into a wholly-owned subsidiary by acquiring the 50% stake held by its French partner, Atlantic, for approximately ₹2.79 crore. The company will also invest up to ₹15 crore in Hintastica through a rights issue to provide working capital support. Following the divestment of its manufacturing facility in late 2025, Hintastica has transitioned to a distribution-led model for the 'hindware' water heater brand. Additionally, the board approved a ₹25 crore corporate guarantee to secure Hintastica's credit facilities.
Key Highlights
Acquisition of 5,48,787 equity shares from Atlantic for ~₹2.79 crore, making Hintastica a 100% subsidiary.
Investment of up to ₹15 crore via Rights Issue to capitalize Hintastica for operations and working capital.
Extension of a ₹25 crore corporate guarantee to lenders as security for Hintastica's working capital facilities.
Hintastica reported a turnover of ₹39.72 crore for FY 2025-26, down from ₹59.50 crore in FY 2023-24.
Strategic shift to a distribution and marketing-led business model for the water heater segment under the 'hindware' brand.
👀 What to Watch
Investors should monitor the performance of the water heater segment as the company takes full control and shifts to an asset-light distribution model. The consolidation is a positive move for long-term strategic alignment, though the recent decline in Hintastica's turnover warrants attention.
Hindware Home Innovation to Acquire 100% Stake in Hintastica JV for ₹2.79 Crore
Hindware Home Innovation Limited (HHIL) is transitioning its joint venture, Hintastica Private Limited, into a wholly-owned subsidiary by acquiring the remaining 50% stake from Atlantic for approximately ₹2.79 crore. HHIL will also invest ₹15 crore via a rights issue to provide working capital and has approved a ₹25 crore corporate guarantee for the entity. Hintastica, which focuses on the water heater business, reported a turnover of ₹39.72 crore in FY26, reflecting a decline from ₹58.87 crore in FY25 following the divestment of its manufacturing facility.
Key Highlights
Acquisition of 5,48,787 equity shares from Atlantic for an aggregate consideration of ₹2,78,83,867.
Investment of ₹15 crore in Hintastica through a rights issue to capitalize the entity for working capital needs.
Hintastica will transition from a joint venture to a 100% wholly-owned subsidiary of HHIL.
HHIL to extend a corporate guarantee of ₹25 crore as security for Hintastica's working capital facilities.
Hintastica's turnover has declined from ₹59.50 crore in FY24 to ₹39.72 crore in FY26 following its shift to a distribution-led model.
👀 What to Watch
Investors should monitor the integration of the water heater business and whether the shift to a distribution-led model can reverse the recent revenue decline and improve margins.
Hindware to Acquire 100% Stake in Hintastica for ₹2.79 Cr; Plans ₹15 Cr Rights Issue Investment
Hindware Home Innovation is set to take full control of its joint venture, Hintastica Private Limited, by acquiring the remaining 50% stake from its French partner Atlantic for approximately ₹2.79 crore. Additionally, the company will invest up to ₹15 crore through a rights issue to capitalize Hintastica for working capital and operational continuity. Following these transactions, Hintastica will transition from a joint venture to a wholly-owned subsidiary, focusing on the distribution and marketing of water heaters under the 'hindware' brand.
Key Highlights
Approved investment of up to ₹15 crore in Hintastica Private Limited via a rights issue to support working capital needs.
Acquisition of Atlantic’s 5,48,787 equity shares for approximately ₹2.79 crore, making Hintastica a 100% subsidiary.
Hintastica's turnover for FY 2025-26 was ₹39.72 crore, a decrease from ₹58.87 crore in the previous fiscal year.
Board approved the extension of a ₹25 crore corporate guarantee to secure Hintastica’s working capital facilities.
Hintastica has shifted its business model from manufacturing to a distribution and marketing-led business following the divestment of its factory in late 2025.
👀 What to Watch
Investors should view this as a strategic consolidation that gives Hindware full control over its water heater business. Monitor the subsidiary's performance to see if the shift to a distribution-led model improves margins and stabilizes the declining revenue trend.
Amara Raja Q4 FY26 Revenue Rises 15% to ₹3,530 Cr; Plans ₹1,700 Cr Capex for FY27
Amara Raja Energy & Mobility reported a 15% YoY revenue growth in Q4 FY26, reaching ₹3,530 crores, primarily driven by a 30% surge in 4-wheeler OEM volumes. While the core Lead Acid business maintained healthy adjusted EBITDA margins of 12.3%, consolidated margins were slightly diluted to 10.8% due to investments in the New Energy segment. The company is aggressively expanding its lithium-ion capabilities, having supplied over 1 GWh of packs in FY26 and planning a massive ₹1,500-₹1,700 crore capex for FY27 to fund its Giga factory and storage solutions.
Key Highlights
Q4 FY26 consolidated revenue grew 15% YoY to ₹3,530 crores, with full-year FY26 revenue at ₹13,814 crores.
4-wheeler OEM volumes surged by over 30%, while tubular battery volumes grew by 35% during the quarter.
New Energy business contributed ₹280 crores in Q4, with total investment in the subsidiary reaching ₹1,500 crores.
Company projected a significant FY27 capex of ₹1,500-₹1,700 crores, with ₹1,100-₹1,200 crores dedicated to New Energy projects.
Adjusted Lead Acid business EBITDA margin stood at 12.3% despite rising raw material costs and geopolitical export headwinds.
👀 What to Watch
Investors should focus on the company's successful transition toward New Energy and its ability to maintain lead-acid margins through price hikes. The heavy capex cycle for the Giga factory indicates long-term growth potential but may weigh on short-term free cash flows.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Recommends ₹10 Dividend
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for FY26. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a high base effect from a ₹19.77 crore land sale profit in the previous year. The Board has recommended a dividend of ₹10 per share (100% of face value). Additionally, the company has reappointed Mr. T T Raghunathan as Executive Chairman for a further five-year term starting November 2026.
Key Highlights
Revenue from operations grew 6.96% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net Profit for the year stood at ₹65.68 crore with an EPS of ₹46.48, down from ₹81.66 crore in the previous year.
Recommended a final dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
Recognized an exceptional income of ₹350.41 lakhs in Q4 FY26 pertaining to GST refunds from earlier periods.
Total Assets increased to ₹1,328.74 crore as of March 31, 2026, up from ₹1,281.19 crore in the previous year.
👀 What to Watch
The profit decline is primarily due to non-recurring gains in the previous year rather than operational deterioration; investors should focus on the steady revenue growth and consistent dividend payout. Monitor the impact of the new Wage Structure implementation planned for FY 2026-27.
Aarey Drugs Reports FY26 Results; Total Assets Grow 17% to ₹211.24 Cr
Aarey Drugs & Pharmaceuticals Limited reported its audited financial results for the fiscal year ended March 31, 2026, showing a healthy expansion in its balance sheet. Total assets grew to ₹211.24 crore from ₹180.50 crore in the previous year, while total equity increased to ₹143.69 crore. The company received an unmodified audit opinion, although auditors noted that debtor and creditor balances are subject to confirmation. Additionally, the board reviewed the utilization of funds raised through the preferential issue of convertible warrants.
Key Highlights
Total assets increased by 17% year-on-year to ₹211.24 crore as of March 31, 2026.
Total equity (Share Capital + Other Equity) rose to ₹143.69 crore, up from ₹133.00 crore in FY25.
Current assets, including trade receivables and inventories, reached ₹176.70 crore compared to ₹155.06 crore last year.
The company received an unmodified audit opinion, ensuring the reliability of the reported financial figures.
Board approved the statement of fund utilization for convertible warrants issued via the preferential route.
👀 What to Watch
Investors should focus on the upcoming Profit & Loss statement to evaluate margin trends and monitor the 'Emphasis of Matter' regarding the confirmation of debtor balances, which are significant to the current asset base.
TTK Healthcare FY26 Net Profit Drops 19.5% to ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a 7% year-on-year growth in revenue from operations to ₹857.28 crore for FY26. However, net profit for the year declined significantly to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to higher expenses and exceptional items. The company recognized a net exceptional charge of ₹7.58 crore related to the incremental impact of new Labour Codes on employee benefits. Despite the profit dip, the board has recommended a dividend of ₹10 per equity share (100% of face value).
Key Highlights
Revenue from operations increased 7% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net profit for FY26 fell to ₹65.68 crore, down from ₹81.66 crore in the previous fiscal year.
Earnings Per Share (EPS) declined to ₹46.48 from ₹57.79 in the prior year.
Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
Exceptional items included a ₹7.58 crore charge for Labour Code compliance and a ₹3.50 crore GST refund.
👀 What to Watch
Investors should be cautious as the decline in profitability and EPS suggests margin pressure despite revenue growth. Monitor the impact of the new wage structure and labour codes on future operating margins.
TTK Healthcare FY26 Net Profit at ₹65.68 Cr; Recommends ₹10 Dividend per Share
TTK Healthcare reported a steady performance for FY26 with total income reaching ₹929.43 crore, up from ₹872.75 crore in FY25. Net profit for the year stood at ₹65.68 crore, a decline compared to ₹81.66 crore in the previous year, which was inflated by a significant one-time gain from a land sale. The company has maintained its dividend payout at ₹10 per share (100% of face value). Leadership remains stable with the re-appointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Revenue from operations grew 7% year-on-year to ₹857.28 crore in FY26.
Net Profit for the full year stood at ₹65.68 crore with an EPS of ₹46.48.
Board recommended a dividend of ₹10 per equity share for the financial year ended March 31, 2026.
Exceptional items for the year included a ₹3.50 crore GST refund and a ₹7.58 crore charge related to new Labour Code provisions.
Mr. T T Raghunathan re-appointed as Executive Chairman for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the core operational growth of 7% in revenue, as the bottom-line decline is primarily due to the absence of last year's large exceptional land sale gain. The consistent dividend and leadership continuity provide stability for long-term holders.
TTK Healthcare FY26 Revenue Rises 7% to ₹857 Cr; Declares ₹10 Dividend per Share
TTK Healthcare reported a steady 7% YoY growth in annual revenue to ₹857.28 crore for FY26. However, Profit After Tax (PAT) declined by 19.5% to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a net exceptional charge of ₹4.07 crore and a high base effect from the previous year's exceptional gains. The company has recommended a dividend of ₹10 per share (100%) and approved the reappointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Annual Revenue from Operations increased to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net Profit for FY26 stood at ₹65.68 crore, down from ₹81.66 crore in the previous year.
Recommended a dividend of ₹10 per equity share of ₹10 each for the financial year ended March 31, 2026.
Exceptional items for FY26 included a ₹7.58 crore charge for Labour Code adjustments, partially offset by a ₹3.50 crore GST refund.
Executive Chairman T T Raghunathan reappointed for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the steady top-line growth while monitoring the impact of rising operational expenses on margins. The consistent dividend payout remains a positive for long-term shareholders.
TTK Healthcare Q4 Net Profit Rises to ₹21.76 Cr; ₹10 Dividend Declared
TTK Healthcare reported a strong performance for Q4 FY26, with net profit reaching ₹2,176.21 lakhs, a significant recovery from ₹1,053.26 lakhs in the previous quarter. For the full year FY26, total income grew to ₹92,943.11 lakhs compared to ₹87,274.83 lakhs in FY25. The Board has recommended a 100% dividend of ₹10 per share, reflecting healthy cash flows. Additionally, the company ensured leadership stability by reappointing Mr. T T Raghunathan as Executive Chairman for a five-year term starting November 2026.
Key Highlights
Net profit for Q4 FY26 stood at ₹2,176.21 lakhs, up from ₹1,053.26 lakhs in Q3 FY26.
Recommended a final dividend of ₹10 per equity share (100%) for the financial year 2025-26.
Annual revenue from operations increased to ₹85,728.11 lakhs in FY26 from ₹80,149.34 lakhs in FY25.
Reappointed Mr. T T Raghunathan as Executive Chairman for a further term of 5 years effective Nov 1, 2026.
Cash and cash equivalents improved to ₹2,144.14 lakhs as of March 31, 2026, compared to ₹900.64 lakhs in the previous year.
👀 What to Watch
Investors should consider the strong quarterly earnings and consistent dividend payout as signs of operational stability. The stock remains attractive for those seeking steady returns and management continuity.
